Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2010
09/14/2010US7795301 preventing myxoviruses infection using 3-(acetylamino)-2-{3-(acetylamino)-4-{[amino(imino)methyl]amino}-6-carboxy-3,4-dihydro-2H-pyran-2-yl)-1-[1,2-dihydroxyethyl]-19,20-dihydroxy-3,16-dioxo-2,17-dioxa-4,15-diazaicos-1-yl}-4-{[amino(imino)methyl]-amino}-3,4-dihydro-2H--pyran-6-carboxylic acid; viricides
09/14/2010US7795240 Nonreducing beta-glucan derivative
09/14/2010US7795203 topically applying an aqueous ophthalmic composition comprising N-acetylcarnosine, a N-acetylcarnosine derivative and a cellulose compound which increases intraocular absorption of N-acetylcarnosine; a hydrophilic hydrogel contact lens and an ocular polymer insert for topical application
09/14/2010US7795031 Neurodegenerative disease; demyelination diseases; brain disorders; screening stem cells in brain; animal models; Alzheimer's, Parkinson's, Huntington's disease
09/14/2010US7794762 Canola oil protein micellar mass (PMM) for enhancing nutrient quality of pets foods, animal feed, cosmetic and personal care products
09/14/2010US7794754 Methods for fine powder formation
09/14/2010US7794752 Preparation and administration form comprising an acid-labile active compound
09/14/2010US7794749 comprising L-Arginine, Xanthinol Nicotinate, and yohimbine; bioavailability; Croscarmellose and/or Crospovidone as agents of disintegration
09/14/2010US7794748 Stable oral solid drug composition
09/14/2010US7794747 Stabilization, homogenizing, sterile filtration, dehydration, reconstitution, ultrafiltration; storage stability; taxanes
09/14/2010US7794746 Nutrient mixture containing oligosaccharides; therapy for inflammatory bowel disorders
09/14/2010US7794744 Nutritional modules
09/14/2010US7794738 Compositions and methods for enhancing corticosteroid delivery
09/14/2010US7794722 Natural killer T-cell agonists; vaccines; antigen presenting cells
09/14/2010US7794696 Made from divinyl ethers and diols that may be dimethylol terminated polyamines, polyamides or dendrimers; may be reacted with polynucleotides to form complexes for cell transfection
09/14/2010CA2541292C Vegetable oil formulations for retinoid-containing soft gelatin capsules
09/14/2010CA2521325C Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
09/14/2010CA2482989C Sugar-free hard coatings prepared from liquid maltitol comprising dp4+ fraction
09/14/2010CA2466996C Non-gelatinous capsule shell compositions and capsules using the same
09/14/2010CA2464151C Ribavirin syrup formulations
09/14/2010CA2458744C Anticancer agents and preparation method of the same
09/14/2010CA2456006C Soybean-based biomaterials
09/14/2010CA2386231C Membrane translocating peptide drug delivery system
09/14/2010CA2376159C Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method
09/14/2010CA2347913C Oral administration of adenosine analogs
09/14/2010CA2295140C Stable insulin formulations
09/14/2010CA2290696C Immunopotentiating composition
09/14/2010CA2277911C Compounds and their combinations for the treatment of influenza infection
09/14/2010CA2222217C Use of fibroblast growth factors mutants to stimulate bone growth
09/14/2010CA2146693C Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
09/10/2010WO2010102196A2 Controlled-release ophthalmic vehicles
09/10/2010WO2010102192A2 Non-steroidal anti-inflammatory ophthalmic compositions
09/10/2010WO2010102102A1 Compatibilized electrolyte formulations
09/10/2010WO2010102066A1 Dextran polymer powder for inhalation administration of pharmaceuticals
09/10/2010WO2010102065A1 Pharmaceutical compositions of dextran polymer derivatives
09/10/2010WO2010102020A1 Insulin formulations for rapid uptake
09/10/2010WO2010101627A2 Methods and systems for treatment and/or diagnosis
09/10/2010WO2010101555A1 A process for forming stabilized ophthalmic solutions
09/10/2010WO2010101226A1 Nucleic acid complex and nucleic acid-delivering composition
09/10/2010WO2010101178A1 Amino acid-conjugated cyanoacrylate polymer particles
09/10/2010WO2010101072A1 Drug releasing stent
09/10/2010WO2010100939A1 Oil gelling agent, composition containing oil gelling agent, and external preparation or cosmetic for skin
09/10/2010WO2010100781A1 Composition for nucleic acid delivery
09/10/2010WO2010100479A1 Oral delivery of hydrophilic drugs to the brain
09/10/2010WO2010100430A1 Conjugated proteins and peptides
09/10/2010WO2010100252A1 Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail
09/10/2010WO2010100220A1 Interferon alpha carrier prodrugs
09/10/2010WO2010100218A1 Cationic oil-in-water emulsions containing prostaglandins and uses thereof
09/10/2010WO2010100217A1 Anionic oil-in-water emulsions containing prostaglandins and uses thereof
09/10/2010WO2010100207A1 Pharmaceutical compositions of active pharmaceutical ingredient comprising sulphonylurea moiety with excellent dissolution properties
09/10/2010WO2010083439A3 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
09/10/2010WO2010083434A3 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
09/10/2010WO2010078916A4 Immunocytokines for tumour therapy with chemotherapeutic agents
09/10/2010WO2010070141A3 Microparticles comprising adipose stem cells
09/10/2010WO2010062996A3 Ribavirin composition
09/10/2010WO2010059001A3 Polymer micelle composition for treatment of resistant cancer cells
09/10/2010WO2010058427A3 Process for production and purification of polymyxin b sulfate
09/10/2010WO2010057188A3 Fast-acting, dietary supplement containing compositions and methods of producing the compositions
09/10/2010WO2010053337A3 Slow-release particle and a production method therefor
09/10/2010WO2010053335A3 Method for producing powder containing nanoparticles of insoluble drug, powder produced thereby and pharmaceutical composition containing same
09/10/2010WO2010045321A3 Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
09/10/2010WO2010041279A4 Sustained release drug delivery system
09/10/2010WO2010009451A3 Methods for enhancing the stability of polyorthoesters and their formulations
09/10/2010CA2754770A1 Compatibilized electrolyte formulations
09/10/2010CA2754251A1 Insulin formulations for rapid uptake
09/10/2010CA2754217A1 Methods and systems for treatment and/or diagnosis
09/10/2010CA2754157A1 Cationic oil-in-water emulsions containing prostaglandins and uses thereof
09/10/2010CA2754156A1 Anionic oil-in-water emulsions containing prostaglandins and uses thereof
09/10/2010CA2754140A1 Oral delivery of hydrophilic drugs to the brain
09/10/2010CA2754089A1 Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate
09/10/2010CA2753947A1 Non-steroidal anti-inflammatory ophthalmic compositions
09/10/2010CA2753703A1 Nucleic acid complex and nucleic acid-delivering composition
09/10/2010CA2753638A1 Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail
09/10/2010CA2753001A1 Interferon alpha carrier prodrugs
09/09/2010US20100228343 Phase-separated biocompatible polymer compositions for medical uses
09/09/2010US20100228018 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/09/2010US20100227929 Transdermal compositions
09/09/2010US20100227896 Use of vitamin pp compounds
09/09/2010US20100226999 Process for forming stabilized ophthalmic solutions
09/09/2010US20100226997 Controlled-release ophthalmic vehicles
09/09/2010US20100226996 Compositions and methods of delivery of pharmacological agents
09/09/2010US20100226992 Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye
09/09/2010US20100226985 Viscoelastic aqueous gels comprising microspheres
09/09/2010US20100226974 Antibody recognizing antigen
09/09/2010US20100226970 Cationic liposome delivery of taxanes to angiogenic blood vessels
09/09/2010US20100226964 Highly Compactable and durable direct compression excipients and excipient systems
09/09/2010US20100226963 Bi-functional co-polymer use for opthalmic and other topical and local applications
09/09/2010US20100226954 Polymeric delivery formulations of leuprolide with improved efficacy
09/09/2010US20100226914 Method for preparation of single chain antibodies
09/09/2010DE202010007560U1 Mehrschichtige Einbettungsstruktur, geeignet zum Einbetten von probiotikahaltigen Aktivmittel-Teilchen Multi-layer embedding structure, suitable for embedding probiotikahaltigen active agent particles
09/09/2010DE102009011805A1 Tableting excipient, useful e.g. to produce food supplement and/or feeding stuff, comprises a condensation core and a fat, which is coated to condensation core, where condensation core and fat are connected together by spray drying
09/08/2010EP2226635A1 Immunodetection assay for mycobacterium tuberculosis complex
09/08/2010EP2226318A2 Dye-Azide compounds for dual photherapy
09/08/2010EP2226085A1 Anti-angiogenic compositions and methods of use
09/08/2010EP2226069A1 Edible film
09/08/2010EP2226066A1 Water-containing composition which can be used as external composition
09/08/2010EP2224973A1 Preservatives for cosmetic, toiletry and pharmaceutical compositions
09/08/2010EP2224958A2 Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
09/08/2010EP2224933A2 Conjugated beta-1,3-linked glucans
09/08/2010EP2224914A2 Rhein or diacerein compositions
1 ... 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 ... 1712